Please login to the form below
Gilead
This page shows the latest Gilead news and features for those working in and with pharma, biotech and healthcare.
Gilead’s Jyseleca is given a NICE recommendation for rheumatoid arthritis
In August 2020, the US Food and Drug Administration (FDA) rejected Gilead’s Jyseleca, handing the company a complete response letter (CRL). ... The FDA has expressed concerns regarding the overall benefit/risk profile of the filgotinib 200 mg dose,”
Latest news
-
UPDATED: Gilead says remdesivir likely to be effective against new COVID-19 strains
However, Gilead has remained confident that remdesivir has benefit against both the UK and South African strains. ... However, Gilead hit back at the results from this study, calling them ‘inconsistent’.
-
Merck’s appeal to restore hepatitis C patent verdict against Gilead fails
Gilead alleged in the lawsuit that Merck had amended its patent application in an attempt to extend its coverage to include sofosbuvir. ... Idenix discovered that a single type of modified ribonucleoside inhibits the hepatitis C virus,” said Gilead.
-
Kite and Oxford BioTherapeutics sign oncology research pact
In 2017, Gilead paid $11.9bn to acquire Kite and its pipeline of chimeric antigen receptor T cell (CAR-T) therapies. ... lymphoma. In Gilead’s recent third quarter results, the combined cell therapy products brought in $444m in the first nine months of
-
Gilead set to acquire hepatitis specialist MYR for €1.15bn
According to Gilead, at least 12 million people globally are currently co-infected with HDV and hepatitis B virus (HBV). ... This will build on the work that Gilead has been doing for almost two decades to innovate and improve therapies for viral
-
ASH 2020: Gilead eyes new Yescarta indication, Vertex/CRISPR make headway in sickle cell and more
Gilead eyes new first-line indication for CAR T Yescarta. ... Gilead’s Kite division presented new phase 2 data for its CAR T therapy Yescarta at ASH 2020 in relapsed or refractory high-risk large B-cell lymphoma (LBCL), a potential
More from news
Approximately 183 fully matching, plus 389 partially matching documents found.
Latest Intelligence
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers Squibb’s acquisition of Juno Therapeutics, as well as the merger and acquisition agreements between Novartis/Spark and
-
The search for effective drug treatments for COVID-19
The European Commission has signed a joint procurement agreement for Gilead’s COVID-19 antiviral treatment remdesivir. ... Since January, Gilead has taken multiple steps to ramp up production and rapidly build supply in recognition of the lengthy
-
Switzerland: a life sciences hub
The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Lundbeck, MSD (Merck Sharp &Dohme), Pfizer, Sanofi and Takeda among others.
-
Working together against COVID-19
There were questions asked directly to Gilead, and also peers, about Compassionate Use and Extended Access. ... Subsequently, Gilead dropped remdesivir’s orphan drug designation based on its potential as a coronavirus treatment.
-
COVID-19: the race to find a vaccine
The antiviral subcategory is a key focal point, with drugs such as Gilead Sciences’ remdesivir being tested in tens of trials and attracting the attention of the general public and world
More from intelligence
Approximately 5 fully matching, plus 52 partially matching documents found.
Latest appointments
-
New hires at EMA, Gilead and BeiGene
Gilead. Gilead has appointed Mark Genovese (pictured above) as senior vice president, inflammation. ... In this role, Genovese will oversee the clinical development of Gilead’s investigational portfolio of treatments for inflammatory conditions.
-
Ex-BMS exec jumps to Gilead to lead research group
Gilead has also simultaneously announced the promotion of Linda Higgins, who has recently taken on the role of senior vice president and head of external innovation. ... Higgins (pictured right) joined Gilead in 2010 to lead an expansion of the
-
Ex-Roche CMO Sandra Horning joins Gilead’s board of directors
We are very pleased to welcome Sandra Horning to our Board of Directors,” said Daniel O’Day (pictured right), chairman and chief executive officer of Gilead Sciences. ... Sandra’s presence on our board will be a tremendous asset as we enter the
-
New hires at bluebird bio, BioNTech and Provention Bio
He has also held sales, marketing and medical affairs leadership roles at Sarepta Therapeutics, Vertex Pharmaceuticals and Gilead Sciences.
-
New hires at Abbott, Kite and Arrakis Therapeutics
Kite . Kite, a Gilead company, has appointed two new additions to its leadership team.
More from appointments
Approximately 6 fully matching, plus 20 partially matching documents found.
Latest from PMHub
-
Attigo (part of the Mednet Group)
Clinigen. Crohns and Colitis Department for International Development. Eisai. Gilead. Janssen.
-
90TEN named EMEA Healthcare PR Consultancy of the Year at 2020 SABRE awards
The consultancy was also a finalist for the Best Digital Campaign category for its ‘HIV Garage’ programme for Gilead Sciences.
-
Understanding the evolving CAR-T market
Big pharma also wanted a slice of the action. Aggressive deal-making quickly became central to the rise of CAR-T, with Gilead acquiring Kite Pharma for a mammoth $11.9bn
-
90TEN named Best Agency in Continental Europe at PRWeek Global Awards
The consultancy also scooped awards for Best Campaign in Continental Europe and Best Global Influencer Marketing Campaign for Gilead’s Flight HIV101. ... Refreshing self-awareness”. 90TEN’s Flight HIV101 campaign, on behalf of Gilead, aimed to help
-
Winners of the HSJ Partnership Awards 2019 unveiled
Best Pharmaceutical Partnership with the NHS - Gilead Sciences, CGL and the NHS.
More from PMHub
Approximately 1 fully matching, plus 16 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Senior Account Manager
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Account Director
-
Competitive
-
Medical Editor
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Nucleus Global announces a trio of promotions
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Pfizer introduces new logo in a ‘shift from commerce to science’
- Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
- Pfizer, BioNTech temporarily slow down shipments of COVID-19 vaccine to EU
- Lilly’s antibody bamlanivimab cuts COVID-19 risk by up to 80%
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
